Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of RGB-02 vs Neulasta in breast cancer patients receiving AT chemotherapy
2013-003166-14Phase 3Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RGB-02 in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) (2 arms), sponsored by Gedeon Richter Plc. Primary endpoint: Duration of severe neutropenia in Cycle 1. Started Sep 2013; status: completed.
02
Drugs
RGB-02
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on 2013-003166-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003166-14.